|
|
|
| The change of serum asprosin level in patients with type 2 diabetes
plus nonalcoholic fatty liver disease and the influencing factors |
| LI Hao-xiang, XU Meng-jiao, YUAN Jing, DING Yi, YANG Ling, WANG Dong, ZHAO Li, YUAN Guo-yue |
| （Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001, China）
|
|
|
|
|
Abstract Objective: To investigate the change of serum asprosin level in patients with type 2 diabetes(T2DM) plus nonalcoholic fatty liver disease(NAFLD) and the influencing factors. Methods: Fifty T2DM cases without NAFLD(T2DM group) and 46 T2DM patients with NAFLD(T2DM plus NAFLD group) were selected. Serum asprosin was measured using ELISA method. Body mass index(BMI), waist hip rate(WHR), atherogenic index of plasma（AIP） and HOMAIR were calculated. Results: The asprosin levels were significantly higher in T2DM plus NAFLD group than that in T2DM group \[(1.85±0.79) vs (1.39±0.56) ng/mL, P<0.01\]. The correlation analysis revealed that serum asprosin levels were positively associated with the duration of T2DM,BMI,triglyceride and AIP. The duration of T2DM was the independent correlation factors for asprosin. With increasing of serum asprosin levels, the prevalence of NAFLD in Q1, Q2, Q3 gradually increased as 37.50％, 43.75％, 62.50％ respectively (P<0.05), the value of duration of T2DM, triglyceride and AIP increased gradually(P<0.05 or P<0.01). Conclusion: T2DM plus NAFLD group had significantly higher asprosin levels in comparison with T2DM group, indicating that asprosin may be involved in the development of T2DM plus NAFLD.
|
|
|
|
|
|
| ［1］中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病防治指南(2018年更新版)\[J\]. 实用肝脏病杂志, 2018, 21(2) :177-186.［2］Lin X, Zhang Z, Chen JM, et al. Role of APN and TNFα in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease\[J\]. Genet Mol Res, 2015, 14(2):2940-2946.［3］Ge JF, Walewski JL, Anglade D, et al. Regulation of hepatocellular fatty acid uptake in mouse models of fatty liver disease with and without functional leptin signaling: Roles of NFκB and SREBP1C and the effects of spexin\[J\]. Semin Liver Dis, 2016, 36(4):360-372.［4］Swellam M, Hamdy N. Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor\[J\]. IUBMB Life, 2012, 64(2):180-186.［5］Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fastinginduced glucogenic protein hormone \[J\]. Cell, 2016, 165(3):566-579.［6］Ionescu DF, Niciu MJ, Mathews DC, et al. Neurobiology of anxious depression: a review\[J\]. Depress Anxiety, 2013, 30(4):374-385.［7］罗红. 2型糖尿病与非糖尿病患者非酒精性脂肪肝发病情况的临床分析\[J\]. 临床军医杂志, 2013, 41(4):345-346.［8］Zhang L, Chen C, Zhou N, et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride\[J\]. Clin Chim Acta, 2017，Nov 3. pii: S0009—8981(17)304308. doi: 10.1016/j.cca.2017.10.034. \[Epub ahead of print\]［9］Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone\[J\]. Nat Med, 2017, 23(12):1444-1453.［10］Acara AC, Bolatkale M, Kzlogˇlu I, et al. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin\[J\]. Am J Emerg Med, 2018，36（8）：1504-1505.［11］朱丽雯, 谭延振, 罗文平,等. Asprosin的表达纯化及其对小鼠在体心脏功能的作用\[J\]. 中国实验动物学报, 2017, 25(4):368-372. |
| [1] |
GU Wen-Wen, LI Guo-Min, DING Yi, YUAN Xia. [J]. Journal of Jiangsu University(Medicine Edition), 2019, 29(03): 273-276. |
|
|
|
|
2019, Vol. 29 
